Results for untargeted MS search on m/z: (+/-) mode
| Details | Name | m/z | RT | RT_Units | Study | Ion_mode | MS_Instrument | Chromatography | Species | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| AN002674 | FA (10:0) (capric acid) [M-H]- | 171.1384 | 85.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (11:0) (undecylic acid) [M-H]- | 185.1542 | 91.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (12:0) (lauric acid) [M-H]- | 199.17 | 255 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (13:0) (tridecylic acid) [M-H]- | 213.1856 | 72.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (14:1) (physeteric acid) [M-H]- | 225.1857 | 143.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (14:0) (myristic acid) [M-H]- | 227.2016 | 144 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (15:1) [M-H]- | 239.2014 | 84 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (15:0) (pentadecylic acid) [M-H]- | 241.2172 | 169.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (16:1) (palmitoleic acid) [M-H]- | 253.2173 | 154.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (16:0) (palmitic acid) [M-H]- | 255.2331049 | 189 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | 1_FA iSTD (16:0)-d3 [M-H]- | 258.2521035 | 189 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA 17:1[M-H]- | 267.2331 | 79.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (17:0) (margaric acid) [M-H]- | 269.2488 | 190.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (18:3) (linolenic acid) [M-H]- | 277.2174 | 135 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (18:2) (linoleic acid) [M-H]- | 279.2337001 | 169.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (18:1) (oleic acid) [M-H]- | 281.2490175 | 193.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (18:0) (stearic acid) [M-H]- | 283.2638744 | 221.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA 18:0[M-H]- | 283.2642 | 219.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA 20:5[M-H]- | 301.2172 | 130.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (20:5) (eicosapentaenoic acid) [M-H]- | 301.2172 | 130.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (20:4) (arachidonic acid) [M-H]- | 303.233 | 162 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (20:3) (eicosatrienoic acid) [M-H]- | 305.2484 | 189 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (20:3) (homo-gamma-linolenic acid) [M-H]- | 305.2486 | 181.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (20:2) (eicosadienoic acid) [M-H]- | 307.2643 | 199.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (20:2) (eicosadienoic acid) minor [M-H]- | 307.2644 | 199.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (20:1) (eicosenoic acid) [M-H]- | 309.28 | 225 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (20:0) (arachidic acid) [M-H]- | 311.2957 | 253.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (22:6) (docosahexaenoic acid) [M-H]- | 327.2329 | 153 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (22:1) (erucic acid) [M-H]- | 337.3114 | 258 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | 1_CUDA iSTD [M-H]- | 339.2653863 | 45 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (24:1) (nervonic acid) [M-H]- | 365.3425 | 297 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (24:0) (lignoceric acid) [M-H]- | 367.3581 | 340.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | 1_MAG (17:0/0:0/0:0) iSTD [M+FA-H]- | 389.29085 | 183.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FA (26:0) (cerotic acid) [M-H]- | 395.3894 | 363.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (26:2); FAHFA (18:2/O-8:0) [M-H]- | 421.3323135 | 184.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (26:1); FAHFA (18:1/O-8:0) [M-H]- | 423.3479635 | 205.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (26:1); FAHFA (10:0/O-16:1) [M-H]- | 423.3479635 | 211.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (26:0); FAHFA (10:0/O-16:0) [M-H]- | 425.3636135 | 216.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (26:0); FAHFA (16:0/O-10:0) [M-H]- | 425.3636135 | 225.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (26:0); FAHFA (18:0/O-8:0) [M-H]- | 425.3636135 | 231.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (28:2); FAHFA (18:2/O-10:0) [M-H]- | 449.3636135 | 207.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (28:2); FAHFA (10:1/O-18:1) [M-H]- | 449.3636135 | 216 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (28:2); FAHFA (12:0/O-16:2) [M-H]- | 449.3636135 | 223.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (28:2); FAHFA (12:1/O-16:1) [M-H]- | 449.3636135 | 228 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (28:1); FAHFA (18:1/O-10:0) [M-H]- | 451.3792635 | 229.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (28:1); FAHFA (10:0/O-18:1) [M-H]- | 451.3792635 | 233.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (28:1); FAHFA (12:0/O-16:1) [M-H]- | 451.3792635 | 237.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (28:1); FAHFA (14:0/O-14:1) [M-H]- | 451.3792635 | 251.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPE (16:0) [M-H]- | 452.2775747 | 87 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (28:0); FAHFA (12:0/O-16:0) [M-H]- | 453.3949135 | 246.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (28:0); FAHFA (18:0/O-10:0) [M-H]- | 453.3949135 | 258 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | 1_LPE (17:1) iSTD [M-H]- | 464.2774753 | 77.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPE 17:0[M-H]- | 466.2939 | 108.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (30:3); FAHFA (14:1/O-16:2) [M-H]- | 475.3792635 | 226.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (30:3); FAHFA (12:2/O-18:1) [M-H]- | 475.3792635 | 230.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (30:3); FAHFA (14:2/O-16:1) [M-H]- | 475.3792635 | 230.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (30:3); FAHFA (16:1/O-14:2) [M-H]- | 475.3792635 | 230.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPE (18:2) [M-H]- | 476.2795096 | 72 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (30:2); FAHFA (14:1/O-16:1) [M-H]- | 477.3949135 | 241.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (30:2); FAHFA (12:1/O-18:1) [M-H]- | 477.3949135 | 243 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (30:2); FAHFA (16:1/O-14:1) [M-H]- | 477.3949135 | 243 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (30:2); FAHFA (12:0/O-18:2) [M-H]- | 477.3949135 | 247.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (30:2); FAHFA (14:0/O-16:2) [M-H]- | 477.3949135 | 254.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (30:1); FAHFA (14:1/O-16:0) [M-H]- | 479.4105635 | 251.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (30:1); FAHFA (12:0/O-18:1) [M-H]- | 479.4105635 | 265.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (30:1); FAHFA (14:0/O-16:1) [M-H]- | 479.4105635 | 270.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (30:1); FAHFA (16:0/O-14:1) [M-H]- | 479.4105635 | 286.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPE 18:0[M-H]- A | 480.3088578 | 134.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPE 18:0[M-H]- B | 480.3099 | 123.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (30:0); FAHFA (14:0/O-16:0) [M-H]- | 481.4262135 | 281.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (31:1); FAHFA (13:0/O-18:1) [M-H]- | 493.4262135 | 280.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (31:1); FAHFA (14:0/O-17:1) [M-H]- | 493.4262135 | 286.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (31:1); FAHFA (15:0/O-16:1) [M-H]- | 493.4262135 | 289.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (31:0); FAHFA (15:0/O-16:0) [M-H]- | 495.4418635 | 300.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPG 17:0[M-H]- | 497.289 | 75 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (32:5); FAHFA (16:4/O-16:1) [M-H]- | 499.3792635 | 217.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (32:5); FAHFA (16:3/O-16:2) [M-H]- | 499.3792635 | 222.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPE (20:4) [M-H]- | 500.2776195 | 70.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (32:4); FAHFA (14:2/O-18:2) [M-H]- | 501.3949135 | 237.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (32:4); FAHFA (14:3/O-18:1) [M-H]- | 501.3949135 | 237.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (32:4); FAHFA (16:3/O-16:1) [M-H]- | 501.3949135 | 237.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPE 20:3[M-H]- | 502.2931 | 85.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (32:3); FAHFA (14:1/O-18:2) [M-H]- | 503.4105635 | 251.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (32:3); FAHFA (16:2/O-16:1) [M-H]- | 503.4105635 | 256.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (32:3); FAHFA (16:1/O-16:2) [M-H]- | 503.4105635 | 258 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (32:3); FAHFA (14:2/O-18:1) [M-H]- | 503.4105635 | 261.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (32:3); FAHFA (18:1/O-14:2) [M-H]- | 503.4105635 | 261.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (32:2); FAHFA (14:1/O-18:1) [M-H]- | 505.4262135 | 271.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (32:2); FAHFA (16:1/O-16:1) [M-H]- | 505.4262135 | 275.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (32:2); FAHFA (18:1/O-14:1) [M-H]- | 505.4262135 | 280.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (32:2); FAHFA (14:0/O-18:2) [M-H]- | 505.4262135 | 281.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (32:2); FAHFA (16:0/O-16:2) [M-H]- | 505.4262135 | 289.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (32:1); FAHFA (16:1/O-16:0) [M-H]- | 507.4418635 | 284.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (32:1); FAHFA (14:0/O-18:1) [M-H]- | 507.4418635 | 302.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (32:1); FAHFA (16:0/O-16:1) [M-H]- | 507.4418635 | 307.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (32:0); FAHFA (16:0/O-16:0) [M-H]- | 509.4575135 | 319.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPC (14:0) [M+FA-H]- | 512.29975 | 56.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (33:3); FAHFA (17:1/O-16:2) [M-H]- | 517.4262135 | 273.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (33:2); FAHFA (15:0/O-18:2) [M-H]- | 519.4418635 | 293.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (33:2); FAHFA (15:1/O-18:1) [M-H]- | 519.4418635 | 293.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (33:2); FAHFA (16:1/O-17:1) [M-H]- | 519.4418635 | 293.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (33:2); FAHFA (17:1/O-16:1) [M-H]- | 519.4418635 | 293.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (33:2); FAHFA (18:1/O-15:1) [M-H]- | 519.4418635 | 293.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (33:1); FAHFA (17:1/O-16:0) [M-H]- | 521.4575135 | 303 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (33:1); FAHFA (15:0/O-18:1) [M-H]- | 521.4575135 | 316.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (33:1); FAHFA (16:0/O-17:1) [M-H]- | 521.4575135 | 324.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (33:1); FAHFA (16:1/O-17:0) [M-H]- | 521.4575135 | 324.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (33:0); FAHFA (15:0/O-18:0) [M-H]- | 523.4731635 | 333 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (33:0); FAHFA (17:0/O-16:0) [M-H]- | 523.4731635 | 333.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (33:0); FAHFA (16:0/O-17:0) [M-H]- | 523.4731635 | 339.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPE (22:6) [M-H]- | 524.2786 | 67.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPE 22:5[M-H]- | 526.2941 | 86.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPC 15:0[M+FA-H]- | 526.31505 | 69.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (34:5); FAHFA (16:4/O-18:1) [M-H]- | 527.4105635 | 240.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (34:5); FAHFA (18:3/O-16:2) [M-H]- | 527.4105635 | 243 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPE 22:4[M-H]- | 528.3099 | 98.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (34:4); FAHFA (16:3/O-18:1) [M-H]- | 529.4262135 | 260.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (34:4); FAHFA (18:2/O-16:2) [M-H]- | 529.4262135 | 265.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (34:3); FAHFA (18:3/O-16:0) [M-H]- | 531.4418635 | 267.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (34:3); FAHFA (18:2/O-16:1) [M-H]- | 531.4418635 | 282 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (34:3); FAHFA (16:1/O-18:2) [M-H]- | 531.4418635 | 282.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (34:3); FAHFA (18:1/O-16:2) [M-H]- | 531.4418635 | 292.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (34:2); FAHFA (18:2/O-16:0) [M-H]- | 533.4575135 | 292.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (34:2); FAHFA (16:1/O-18:1) [M-H]- | 533.4575135 | 306 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (34:2); FAHFA (18:1/O-16:1) [M-H]- | 533.4575135 | 309 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (34:2); FAHFA (16:0/O-18:2) [M-H]- | 533.4575135 | 321 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (34:1); FAHFA (18:1/O-16:0) [M-H]- | 535.4731635 | 321.9 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (34:1); FAHFA (14:0/O-20:1) [M-H]- | 535.4731635 | 332.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (34:1); FAHFA (16:0/O-18:1) [M-H]- | 535.4731635 | 342 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (34:1); FAHFA (18:0/O-16:1) [M-H]- | 535.4731635 | 348.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (34:0); FAHFA (16:0/O-18:0) [M-H]- | 537.4888135 | 360.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (34:0); FAHFA (18:0/O-16:0) [M-H]- | 537.4888135 | 360.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPC (16:1) [M+FA-H]- | 538.3144491 | 63 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPC 16:0[M+FA-H]- | 540.3306 | 87 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPC (16:0) [M+FA-H]- | 540.3312907 | 87 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d32:1) [M+Cl]- | 544.4506 | 301.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (35:3); FAHFA (17:1/O-18:2) [M-H]- | 545.4575135 | 296.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (35:3); FAHFA (18:2/O-17:1) [M-H]- | 545.4575135 | 296.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (35:2); FAHFA (18:1/O-17:1) [M-H]- | 547.4731635 | 313.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (35:2); FAHFA (17:1/O-18:1) [M-H]- | 547.4731635 | 325.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (35:2); FAHFA (17:0/O-18:2) [M-H]- | 547.4731635 | 334.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (35:1); FAHFA (18:1/O-17:0) [M-H]- | 549.4888135 | 340.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (35:1); FAHFA (17:0/O-18:1) [M-H]- | 549.4888135 | 355.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (35:1); FAHFA (18:0/O-17:1) [M-H]- | 549.4888135 | 365.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (36:6); FAHFA (18:3/O-18:3) [M-H]- | 553.4262135 | 246.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (36:6); FAHFA (16:0/O-20:6) [M-H]- | 553.4262135 | 27 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (36:6); FAHFA (18:0/O-18:6) [M-H]- | 553.4262135 | 27 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | 1_LPC (17:0) iSTD [M+FA-H]- | 554.3459919 | 108.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPC 17:0[M+FA-H]- | 554.3467 | 107.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d32:1) [M+FA-H]- | 554.47895 | 301.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (36:5); FAHFA (18:3/O-18:2) [M-H]- | 555.4418635 | 262.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (36:4); FAHFA (18:3/O-18:1) [M-H]- | 557.4575135 | 288 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (36:4); FAHFA (18:2/O-18:2) [M-H]- | 557.4575135 | 292.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (36:4); FAHFA (18:1/O-18:3) [M-H]- | 557.4575135 | 297 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d33:1) [M+Cl]- | 558.4656 | 322.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (36:3); FAHFA (18:2/O-18:1) [M-H]- | 559.4731635 | 314.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (36:3); FAHFA (18:1/O-18:2) [M-H]- | 559.4731635 | 318 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (36:2); FAHFA (18:1/O-18:1) [M-H]- | 561.4888135 | 345.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (36:2); FAHFA (18:0/O-18:2) [M-H]- | 561.4888135 | 349.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPC 18:3[M+FA-H]- | 562.31575 | 56.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (36:1); FAHFA (18:1/O-18:0) [M-H]- | 563.5044635 | 360.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (36:1); FAHFA (16:0/O-20:1) [M-H]- | 563.5044635 | 373.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (36:1); FAHFA (18:0/O-18:1) [M-H]- | 563.5044635 | 384.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPC 18:2[M+FA-H]- | 564.3300616 | 71.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPC (18:2) [M+FA-H]- | 564.33105 | 72 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (36:0); FAHFA (18:0/O-18:0) [M-H]- | 565.5201135 | 400.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPC (18:1) [M+FA-H]- | 566.3464374 | 96 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPC 18:1[M+FA-H]- | 566.3468 | 95.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPC (18:0) A [M+FA-H]- | 568.3613453 | 122.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPC (18:0) B [M+FA-H]- | 568.3617785 | 133.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPC 18:0[M+FA-H]- | 568.3625 | 132.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d33:1) [M+FA-H]- | 568.49475 | 321.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d34:1) [M+Cl]- | 572.4816 | 342.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d34:0) [M+Cl]- | 574.4973 | 355.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d34:2) [M+FA-H]- | 580.49525 | 308.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d34:1) [M+FA-H]- | 582.5097831 | 342 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (38:5); FAHFA (20:4/O-18:1) [M-H]- | 583.4731635 | 3 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d34:0) [M+FA-H]- | 584.52605 | 356.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (38:4); FAHFA (18:2/O-20:2) [M-H]- | 585.4888135 | 318 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (38:4); FAHFA (20:3/O-18:1) [M-H]- | 585.4888135 | 322.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPC 20:5[M+FA-H]- | 586.31575 | 55.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | 1_Ceramide (d18:1/17:0) iSTD [M+Cl]- | 586.4960498 | 363 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPC 20:4[M+FA-H]- | 588.3294998 | 70.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (38:2); FAHFA (18:1/O-20:1) [M-H]- | 589.5201135 | 376.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (38:2); FAHFA (20:1/O-18:1) [M-H]- | 589.5201135 | 384 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPC (20:3) [M+FA-H]- | 590.3460831 | 83.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPC (20:2) [M+FA-H]- | 592.36215 | 106.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPI 18:2[M-H]- | 595.2889 | 45.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | 1_Ceramide (d18:1/17:0) iSTD [M+FA-H]- | 596.5260169 | 363 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPI 18:0[M-H]- | 599.3212 | 81.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d36:1) [M+Cl]- | 600.5133 | 384.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (40:7); FAHFA (18:1/O-22:6) [M-H]- | 607.4731635 | 288.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (40:7); FAHFA (22:6/O-18:1) [M-H]- | 607.4731635 | 288.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d36:1) [M+FA-H]- | 610.54195 | 384 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPC 22:6[M+FA-H]- | 612.32675 | 67.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (40:4); FAHFA (16:0/O-24:4) [M-H]- | 613.5201135 | 373.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPC (22:5) [M+FA-H]- | 614.34665 | 76.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPC 22:4[M+FA-H]- | 616.36225 | 97.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | LPI 20:4[M-H]- | 619.2896 | 44.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (40:0); FAHFA (16:0/O-24:0) [M-H]- | 621.5827135 | 472.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d38:1) [M+Cl]- | 628.5445 | 426.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (42:6); FAHFA (18:2/O-24:4) [M-H]- | 637.5201135 | 340.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d38:1) [M+FA-H]- | 638.57335 | 426 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (42:5); FAHFA (18:1/O-24:4) [M-H]- | 639.5357635 | 373.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d39:1) [M+Cl]- | 642.5602 | 447 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (42:1); FAHFA (18:1/O-24:0) [M-H]- | 647.5983635 | 474.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d39:1) [M+FA-H]- | 652.58915 | 447 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d40:2) [M+Cl]- | 654.5603 | 432 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d40:1) [M+Cl]- | 656.5762 | 466.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d40:0) [M+Cl]- | 658.5917 | 48 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d40:2) [M+FA-H]- | 664.58885 | 432 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d40:1) [M+FA-H]- | 666.60505 | 466.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d40:0) [M+FA-H]- | 668.61995 | 479.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d41:1) [M+Cl]- | 670.5922 | 486 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | FAHFA (44:1); FAHFA (26:0/O-18:1) [M-H]- | 675.6296635 | 538.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | 1_PC (12:0/13:0) iSTD [M+FA-H]- | 680.447887 | 214.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d41:1) [M+FA-H]- | 680.62085 | 486 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d42:2) B [M+Cl]- | 682.5918 | 471.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d42:2) A [M+Cl]- | 682.5923 | 464.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d42:1) [M+Cl]- | 684.6077 | 504.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d42:0) [M+Cl]- | 686.623 | 517.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 32:1PE 16:0-16:1[M-H]- | 688.4933 | 308.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d30:1) [M+FA-H]- | 691.50415 | 220.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d42:2) A [M+FA-H]- | 692.6192479 | 464.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d42:2) B [M+FA-H]- | 692.62075 | 471.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d42:1) [M+FA-H]- | 694.63665 | 504.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d42:0) [M+FA-H]- | 696.65185 | 517.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE (p-34:2) or PE (o-34:3) [M-H]- | 698.511332 | 333.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d43:1) [M+Cl]- | 698.6231 | 516 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE (p-34:1) or PE (o-34:2) [M-H]- | 700.529 | 364.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 34:1ePE 16:0e/18:1[M-H]- | 702.5429 | 370.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM d31:1SM d15:0/16:1[M+FA-H]- | 705.51945 | 236.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d43:1) [M+FA-H]- | 708.65195 | 516 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d32:1) [M+Cl]- | 709.5062 | 253.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 34:3PE 16:0-18:3[M-H]- | 712.4935 | 295.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d44:1) [M+Cl]- | 712.6387 | 54 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE (34:2) [M-H]- | 714.505867 | 315 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE (34:1) [M-H]- | 716.5245 | 345.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d32:2) [M+FA-H]- | 717.51985 | 226.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | 1_PE (17:0/17:0) iSTD [M-H]- | 718.538132 | 380.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d32:1) [M+FA-H]- | 719.5335974 | 253.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM d32:1SM d14:0/18:1[M+FA-H]- | 719.5358 | 253.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE (p-36:5) or PE (o-36:6) [M-H]- | 720.4985 | 301.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d32:0) [M+FA-H]- | 721.55035 | 265.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE (p-36:4) or PE (o-36:5) [M-H]- | 722.5112079 | 326.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 36:5ePE 18:3e/18:2[M-H]- | 722.5139 | 309 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | Ceramide (d44:1) [M+FA-H]- | 722.66755 | 54 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 36:4ePE 18:2e/18:2[M-H]- | 724.5297 | 337.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE (p-36:2) or PE (o-36:3) [M-H]- | 726.5431226 | 373.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE (p-36:1) or PE (o-36:2) [M-H]- | 728.5608 | 405 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d33:1) [M+FA-H]- | 733.5487927 | 270.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 36:5PE 16:0-20:5[M-H]- | 736.4932 | 285 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d34:1) [M+Cl]- | 737.5375 | 288.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE (36:4) [M-H]- | 738.506409 | 309.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 36:4PE 18:2-18:2[M-H]- | 738.5093 | 294.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE (36:3) [M-H]- | 740.5248 | 318.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE (36:2) [M-H]- | 742.5367862 | 354.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 36:2PE 18:1-18:1[M-H]- | 742.5402 | 349.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE (36:1) [M-H]- | 744.552412 | 338.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d34:2) [M+FA-H]- | 745.5493642 | 258.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM d34:2SM d18:2/16:0[M+FA-H]- | 745.5516 | 259.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE (p-38:6) or PE (o-38:7) [M-H]- | 746.5111522 | 315.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 38:7ePE 18:3e/20:4[M-H]- | 746.5145 | 302.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PG 34:1PG 16:0-18:1[M-H]- | 747.519 | 277.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM d34:1SM d18:1/16:0[M+FA-H]- | 747.5660915 | 289.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d34:1) [M+FA-H]- | 747.56695 | 289.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE (p-38:5) or PE (o-38:6) [M-H]- | 748.5269523 | 329.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 38:6ePE 18:1e/20:5[M-H]- | 748.5298 | 339 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | 1_PG (17:0/17:0) iSTD [M-H]- | 749.5339987 | 336.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d34:0) [M+FA-H]- | 749.579219 | 303 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | GlcCer(d14:1(4E)/20:0(2OH)) [M+Cl]- | 750.5311 | 294.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE (p-38:4) or PE (o-38:5) [M-H]- | 750.5426772 | 366.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 38:5ePE 16:1e/22:4[M-H]- | 750.545 | 354.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 37:4PE 17:0-20:4[M-H]- | 752.5242 | 328.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 38:4ePE 18:0e/20:4[M-H]- | 752.5605 | 373.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE (p-38:3) or PE (o-38:4) [M-H]- | 752.5605 | 383.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE (p-38:2) or PE (o-38:3) [M-H]- | 754.5767 | 413.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM d35:2SM d17:0/18:2[M+FA-H]- | 759.56655 | 277.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | GlcCer(d14:1(4E)/20:0(2OH)) [M+FA-H]- | 760.55965 | 294.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | 1_SM (d18:1/17:0) iSTD [M+FA-H]- | 761.5789623 | 309.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE (38:6) [M-H]- | 762.5056162 | 296.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 38:6PE 18:2-20:4[M-H]- | 762.509 | 285 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (p-32:0) or PC (o-32:1) [M+FA-H]- | 762.5639766 | 351.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 38:5PE 16:0-22:5[M-H]- | 764.5242 | 324 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 38:5PE 18:1-20:4[M-H]- | 764.528964 | 312.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (o-32:0) [M+FA-H]- | 764.5772207 | 358.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE (38:4) B [M-H]- | 766.537731 | 348 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 38:4PE 16:0-22:4[M-H]- | 766.54 | 336.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 38:3PE 18:0-20:3[M-H]- | 768.5555 | 364.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d36:3) [M+FA-H]- | 771.56715 | 268.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE (p-40:7) or PE (o-40:8) [M-H]- | 772.5297 | 318.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PG 36:2PG 18:0-18:2[M-H]- | 773.5345 | 286.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d36:2) [M+FA-H]- | 773.581765 | 296.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM d36:2SM d14:0/22:2[M+FA-H]- | 773.5826 | 295.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (32:2) [M+FA-H]- | 774.5257798 | 272.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE (p-40:6) or PE (o-40:7) [M-H]- | 774.5422137 | 354.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 40:7ePE 18:2e/22:5[M-H]- B | 774.5448 | 331.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 40:7ePE 18:2e/22:5[M-H]- A | 774.5453 | 337.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d36:1) [M+FA-H]- | 775.5959426 | 329.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM d36:1SM d14:0/22:1[M+FA-H]- | 775.5984 | 33 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC 32:1PC 16:0-16:1[M+FA-H]- | 776.5425018 | 3 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (32:1) [M+FA-H]- | 776.54615 | 300.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE (p-40:5) or PE (o-40:6) [M-H]- | 776.5575401 | 367.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 40:6ePE 18:1e/22:5[M-H]- | 776.5609 | 381.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PG 36:0PG 17:0-19:0[M-H]- | 777.5658 | 342.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d36:0) [M+FA-H]- | 777.61355 | 343.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC 32:0PC 16:0-16:0[M+FA-H]- | 778.5595313 | 333.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (32:0) [M+FA-H]- | 778.56185 | 334.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 40:5ePE 18:1e/22:4[M-H]- | 778.5766 | 394.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE (p-40:4) or PE (o-40:5) [M-H]- | 778.5768 | 406.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 40:5ePE 18:0e/22:5[M-H]- | 778.577 | 374.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (p-34:2) or PC (o-34:3) [M+FA-H]- | 786.5651903 | 325.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (33:2) [M+FA-H]- | 788.5415979 | 290.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (p-34:1) or PC (o-34:2) B [M+FA-H]- | 788.5784837 | 355.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (p-34:1) or PC (o-34:2) A [M+FA-H]- | 788.5785958 | 331.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d37:1) [M+FA-H]- | 789.61325 | 351 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 40:6PE 18:0-22:6[M-H]- | 790.5406 | 337.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (33:1) [M+FA-H]- | 790.5578851 | 319.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (p-34:0) or PC (o-34:1) [M+FA-H]- | 790.5935709 | 361.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | GlcCer (d38:1) [M+Cl]- | 790.5976 | 385.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 40:5PE 18:0-22:5[M-H]- A | 792.5554 | 363.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 40:5PE 18:0-22:5[M-H]- B | 792.5561 | 349.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC 34:0ePC 18:0e/16:0[M+FA-H]- | 792.61355 | 399.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PE 40:4PE 18:0-22:4[M-H]- | 794.5716 | 376.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (34:4) [M+FA-H]- | 798.53065 | 267.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (34:3) [M+FA-H]- | 800.5424938 | 280.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | GlcCer (d38:1) [M+FA-H]- | 800.62605 | 385.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d38:2) [M+FA-H]- | 801.6119372 | 335.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (34:2) [M+FA-H]- | 802.5604236 | 309 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC 34:2PC 16:0-18:2[M+FA-H]- | 802.5618 | 309.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM d38:1SM d14:1/24:0[M+FA-H]- | 803.6265969 | 371.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d38:1) [M+FA-H]- | 803.63005 | 371.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC 34:1PC 16:0-18:1[M+FA-H]- | 804.5754208 | 338.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (34:1) [M+FA-H]- | 804.57775 | 338.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d38:0) [M+FA-H]- | 805.64455 | 385.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (34:0) [M+FA-H]- | 806.5914294 | 373.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PI 32:1PI 16:0-16:1[M-H]- | 807.504 | 241.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d39:1) [M+Cl]- | 807.6162 | 392.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PI 32:0PI 16:0-16:0[M-H]- | 809.5195 | 265.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PS 38:4PS 18:0-20:4[M-H]- | 810.53 | 278.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (p-36:4) or PC (o-36:5) [M+FA-H]- | 810.5634254 | 318 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (35:4) [M+FA-H]- | 812.54635 | 285 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC 36:4ePC 16:1e/20:3[M+FA-H]- | 812.5774737 | 334.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (p-36:3) or PC (o-36:4) [M+FA-H]- | 812.5794321 | 325.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d39:2) [M+FA-H]- | 815.63025 | 356.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (36:4) B [M+Cl]- | 816.5328 | 303 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (35:2) [M+FA-H]- | 816.5735254 | 324 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (p-36:1) or PC (o-36:2) [M+FA-H]- | 816.6107143 | 372.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d39:1) [M+FA-H]- | 817.6430706 | 392.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | OxPC 34:1+1O(1Cyc)OxPC 16:0-18:1+1O(1Cyc)[M+FA-H]- | 818.55655 | 269.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (35:1) [M+FA-H]- | 818.5892257 | 358.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | GlcCer (d40:1) [M+Cl]- | 818.6294 | 426.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (36:1) [M+Cl]- | 822.5801 | 379.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC 36:5PC 16:0-20:5[M+FA-H]- | 824.5428087 | 279.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (36:5) B [M+FA-H]- | 824.54605 | 279.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (36:5) A [M+FA-H]- | 824.54615 | 262.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (36:4) A [M+FA-H]- | 826.5601468 | 285 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (36:4) B [M+FA-H]- | 826.5609621 | 303 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC 36:4PC 16:0-20:4[M+FA-H]- | 826.562 | 303 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d40:3) [M+FA-H]- | 827.63005 | 336 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (36:3) A [M+FA-H]- | 828.5753634 | 312.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (36:3) B [M+FA-H]- | 828.5755592 | 318 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC 36:3PC 16:0-20:3[M+FA-H]- | 828.5777 | 318.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC 36:3PC 18:1-18:2[M+FA-H]- | 828.5778 | 313.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | GlcCer (d40:1) [M+FA-H]- | 828.65795 | 426 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d40:2) A [M+FA-H]- | 829.6429782 | 370.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d40:2) B [M+FA-H]- | 829.6435648 | 376.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM d40:2SM d14:0/26:2[M+FA-H]- | 829.6462 | 377.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (36:2) [M+FA-H]- | 830.5922406 | 346.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC 36:2PC 18:0-18:2[M+FA-H]- | 830.5934 | 347.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM d40:1SM d14:1/26:0[M+FA-H]- | 831.6605 | 412.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d40:1) [M+FA-H]- | 831.66125 | 412.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (36:1) [M+FA-H]- | 832.6058454 | 378.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC 36:1PC 18:0-18:1[M+FA-H]- | 832.6091 | 378.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | GlcCer (d41:1) [M+Cl]- | 832.6455 | 446.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PI 34:2PI 16:0-18:2[M-H]- | 833.5201 | 247.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d40:0) [M+FA-H]- | 833.67635 | 427.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PI 34:1PI 16:0-18:1[M-H]- | 835.5356 | 27 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC 38:6ePC 18:2e/20:4[M+FA-H]- | 836.578477 | 322.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (p-38:5) or PC (o-38:6) [M+FA-H]- | 836.58275 | 314.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PI 34:0PI 16:0-18:0[M-H]- | 837.5507 | 297.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (p-38:4) or PC (o-38:5) B [M+FA-H]- | 838.5937615 | 357.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (p-38:4) or PC (o-38:5) A [M+FA-H]- | 838.5951815 | 328.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC 38:5ePC 18:1e/20:4[M+FA-H]- | 838.59815 | 333.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (37:4) [M+FA-H]- | 840.5729037 | 316.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (p-38:3) or PC (o-38:4) [M+FA-H]- | 840.6099457 | 365.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC 38:3ePC 18:0e/20:3[M+FA-H]- | 842.62825 | 382.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | GlcCer (d41:1) [M+FA-H]- | 842.67385 | 446.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d41:2) [M+FA-H]- | 843.6565362 | 397.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM d41:2SM d14:2/27:0[M+FA-H]- | 843.6624 | 398.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (37:2) [M+FA-H]- | 844.60595 | 360.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d41:1) [M+FA-H]- | 845.67695 | 432.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | GlcCer (d42:1) [M+Cl]- | 846.6606 | 465.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PI 35:2PI 17:0-18:2[M-H]- | 847.5348 | 262.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (38:6) [M+FA-H]- | 850.5588152 | 292.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC 38:6PC 16:0-22:6[M+FA-H]- | 850.5615 | 294.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (38:5) B [M+FA-H]- | 852.5744621 | 315 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC 38:5PC 16:0-22:5[M+FA-H]- | 852.5745882 | 305.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (38:5) A [M+FA-H]- | 852.57735 | 305.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (38:4) A [M+FA-H]- | 854.5912849 | 340.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC 38:4PC 18:0-20:4[M+FA-H]- | 854.5927 | 341.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | GlcCer (d42:2) [M+FA-H]- | 854.67385 | 424.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d42:3) [M+FA-H]- | 855.6584514 | 375.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM d42:3SM d14:2/28:1[M+FA-H]- | 855.6627 | 376.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (38:3) [M+FA-H]- | 856.6064127 | 358.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC 38:3PC 18:0-20:3[M+FA-H]- | 856.609 | 358.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | GlcCer (d42:1) [M+FA-H]- | 856.68955 | 465.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PI 36:4PI 16:0-20:4[M-H]- | 857.5199 | 244.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM d42:2SM d18:1/24:1[M+FA-H]- | 857.6742196 | 410.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM d42:2SM d14:2/28:0[M+FA-H]- | 857.6768 | 418.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d42:2) B [M+FA-H]- | 857.67695 | 418.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d42:2) A [M+FA-H]- | 857.67705 | 410.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (38:2) [M+FA-H]- | 858.62465 | 384 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PI 36:3PI 18:1-18:2[M-H]- A | 859.5353 | 255 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PI 36:3PI 18:1-18:2[M-H]- B | 859.5355 | 250.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM d42:1SM d18:0/24:1[M+FA-H]- | 859.69185 | 424.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM d42:1SM d18:1/24:0[M+FA-H]- | 859.6926 | 453 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d42:1) [M+FA-H]- | 859.69275 | 452.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PI 36:2PI 18:0-18:2[M-H]- | 861.5513 | 277.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PI 36:1PI 18:0-18:1[M-H]- | 863.5667 | 302.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (p-40:4) or PC (o-40:5) [M+FA-H]- | 866.6225991 | 366 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC 40:4ePC 18:0e/22:4[M+FA-H]- | 868.64535 | 394.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (p-40:3) or PC (o-40:4) [M+FA-H]- | 868.64575 | 405.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PI 37:4PI 17:0-20:4[M-H]- | 871.535 | 258 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d43:2) [M+FA-H]- | 871.69245 | 423.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d43:1) [M+FA-H]- | 873.70855 | 465.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM d43:1SM d14:1/29:0[M+FA-H]- | 873.70855 | 472.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (40:6) B [M+FA-H]- | 878.5890532 | 330.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (40:6) A [M+FA-H]- | 878.59205 | 313.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (40:5) A [M+FA-H]- | 880.6048624 | 343.2 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (40:5) B [M+FA-H]- | 880.6071397 | 357 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (40:4) [M+FA-H]- | 882.6206787 | 369.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PI 38:5PI 18:1-20:4[M-H]- | 883.5356 | 251.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PI 38:4PI 18:0-20:4[M-H]- | 885.5515 | 273.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | SM (d44:2) [M+FA-H]- | 885.70895 | 450.6 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PI 38:3PI 18:0-20:3[M-H]- B | 887.5671 | 286.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PI 38:3PI 18:0-20:3[M-H]- A | 887.5672 | 296.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (p-42:5) or PC (o-42:6) [M+FA-H]- | 892.64535 | 371.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (p-42:4) or PC (o-42:5) [M+FA-H]- | 894.66175 | 405 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PI 39:4PI 19:0-20:4[M-H]- | 899.5666 | 289.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PI 40:6PI 18:0-22:6[M-H]- | 909.5511 | 265.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PI 40:5PI 18:0-22:5[M-H]- | 911.5673 | 286.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PI 40:4PI 18:0-22:4[M-H]- | 913.5825 | 295.8 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
| AN002674 | PC (p-44:4) or PC (o-44:5) [M+FA-H]- | 922.69235 | 443.4 | Minutes | ST001636 | NEGATIVE | Agilent 6550 QTOF | Reversed phase | Human | Blood |
